Research · Apr 23, 2026
Radiopharm Theranostics Lands Siemens Deal as Cash Drops to 1.3-Quarter Runway
Radiopharm Theranostics disclosed 1.29 quarters of cash runway in its Q3 FY2026 filing, triggering mandatory ASX sub-2-quarter disclosure requirements. The same filing revealed a material supply agreement with Siemens Healthineers for RAD101, validating the commercial pathway but forcing a capital raise within 60 days. The stock trades at $2.45, down 47% YTD, setting up a binary outcome on financing terms.